Tenstorrent Raises $1.5B for AI Chips; Other Funding Rounds

The artificial intelligence infrastructure sector commanded significant investor attention on October 19, 2026, with Tenstorrent, a U.S.-based AI chip designer, announcing a substantial $1.5 billion Series E funding round. This infusion of capital, which values the company at $6.2 billion, underscores a broader market trend favoring foundational technologies that power advanced computing. The round was spearheaded by Trace Capital and Innovation X, with robust participation from a consortium of prominent financial institutions including ARK Invest, Fidelity Management & Research, Morgan Stanley, T. Rowe Price, SanDisk, Cadence Ventures, Tether Investments, Eclipse, Protagonist, Maverick Silicon, and XTX Markets. This significant investment will fuel Tenstorrent's efforts in scaling its proprietary Galaxy server systems and expanding its commercial reach, particularly its strategy of licensing RISC-V based AI and CPU intellectual property to companies developing custom silicon solutions.

This strategic focus on open computing architecture positions Tenstorrent as a challenger to established players by offering greater customer control over AI hardware and software. The company's CEO, Jim Keller, brings a wealth of experience from leadership roles at tech giants like Apple, AMD, and Tesla, lending considerable technical credibility to the venture. The Series E financing more than doubles Tenstorrent's valuation since its December 2024 funding, equipping it with substantial resources to compete in the high-stakes AI hardware market.

Beyond the headline-grabbing AI hardware deal, the day's funding activity highlighted continued investor confidence in biotechnology and healthcare innovation. European biotechnology firm Nouscom successfully closed a €120 million (approximately $135 million) financing round. This capital is earmarked for advancing its novel cancer-prevention immunotherapy programs, particularly focusing on generating clinical evidence for its Lynch syndrome therapy. The investment was supported by a strong syndicate including lead investors M Ventures and Revelation Partners, alongside Angelini Industries, the European Investment Bank, Neva SGR, 5AM Ventures, Andera Partners, Bpifrance, EQT Life Sciences, Versant Ventures, and CDP Venture Capital. This substantial backing reflects the long-term value investors place on deep scientific research and intellectual property in the biopharmaceutical sector.

In the rapidly expanding Indian healthcare market, Even Healthcare secured $50 million from notable investors Khosla Ventures and Alpha Wave. This funding round values the company at $300 million and signals a growing appetite for integrated healthcare models. Even Healthcare's approach involves merging healthcare financing with direct hospital ownership and employing salaried medical professionals, aiming to reshape the economic dynamics within private healthcare delivery. The capital infusion is intended to support the expansion of its hospital network.

The broader venture capital ecosystem demonstrated continued activity across diverse geographies and sectors. Smaller, yet significant, rounds were observed in areas such as physical AI, enterprise software, and specialized industrial applications. For instance, Manchester-based sports technology firm Rezzil raised $10 million, while Chinese physical-AI startup Gewu Tongzhi garnered nearly RMB100 million. Other companies attracting investment included Saudi Arabia's Vrtx, Sweden's Vessla, Australia's Syncrowin, UK-based compliance software provider CoComply, and Indian apparel e-commerce platform The Pant Project. These varied investments suggest that while large-scale capital is concentrating in capital-intensive technology infrastructure, venture funding remains accessible for innovative solutions addressing specific operational challenges and market needs.

The concentration of capital in AI infrastructure, exemplified by Tenstorrent's massive raise, alongside substantial investments in deep-tech areas like biotechnology, indicates a strategic shift by investors. The emphasis is increasingly on companies controlling unique, hard-to-replicate assets, whether that be processor architecture, proprietary scientific data, manufacturing capabilities, or regulated operational workflows. This trend suggests a maturing venture capital market that prioritizes defensible competitive advantages and long-term technological moats.